Menu
Search
|

Menu

Close
X

Tigenix NV TIG.OQ (NASDAQ Stock Exchange Global Select Market)

41.45 USD
+0.43 (+1.05%)
As of 4:00 PM EDT
chart
Previous Close 41.02
Open 40.98
Volume 402
3m Avg Volume 513
Today’s High 41.45
Today’s Low 40.98
52 Week High 43.94
52 Week Low 19.24
Shares Outstanding (mil) 296.07
Market Capitalization (mil) 526.41
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, EUR)
FY17
0
FY16
25
FY15
2
EPS (EUR)
FY17
-0.283
FY16
0.012
FY15
-0.211
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.04
Price to Sales (TTM)
vs sector
--
8.22
Price to Book (MRQ)
vs sector
22.82
4.29
Price to Cash Flow (TTM)
vs sector
--
22.60
Total Debt to Equity (MRQ)
vs sector
116.75
17.61
LT Debt to Equity (MRQ)
vs sector
21.50
13.12
Return on Investment (TTM)
vs sector
-105.02
13.11
Return on Equity (TTM)
vs sector
-148.10
15.11

EXECUTIVE LEADERSHIP

Jean Stephenne
Independent Chairman of the Board, representing Innoste SA, Since 2012
Salary: --
Bonus: --
Eduardo Bravo Fernandez de Araoz
, Since
Salary: --
Bonus: --
Claudia D'Augusta
Chief Financial Officer, Chief Compliance Officer, Company Secretary, Since 2011
Salary: --
Bonus: --
Wilfried Dalemans
Chief Technology Officer, Since
Salary: --
Bonus: --
Gil Beyen
Chief Business Officer, Managing Director, Executive Director, representing of Gil Beyen BVBA, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Box 2, Romeinse Straat 12
HEVERLEE     3001

Phone: +3216.396060

TiGenix NV is a Belgium-based biopharmaceutical company focused on the development and commercialization of therapeutics from its platforms of allogeneic, or donor-derived, expanded stem cells. The Company's two products from the adipose-derived stem cell platform are in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients, and Cx611 which has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. From the Company's cardiac stem cell-based platform are AlloCSC-01 with a Phase II clinical trial in Acute Myocardial Infarction, and AlloCSC-02 being developed for a chronic indication. TiGenix NV operates in the domestic market and in Madrid, Spain.

SPONSORED STORIES